References
- Baldessarini R J, Cohen B M, Teicher M H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry 1988; 45: 79–91
- Farde L, Wiesel F, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Archives of General Psychiatry 1988; 45: 71–76
- Baldessarini R J, Katz B, Cotton P. Dissimilar dosing with high-potency and low-potency neuroleptics. American Journal of Psychiatry 1984; 141: 748–752
- Inderbitzin L B, Lewine R RJ, Gloersen B A, Rosen P B, McDonald S C, Vidanagama B P. Fluphenazine decanoate: a clinical problem?. American Journal of Psychiatry 1989; 146: 88–91
- Reardon G T, Rifkin A, Schwartz A, Myerson A, Siris S G. Changing patterns of neuroleptic dosage over a decade. American Journal of Psychiatry 1989; 146: 726–729
- Brotman A W, McCormick S. Converting doses of fluphenazine decanoate to oral equivalents (letter). American Journal of Psychiatry 1989; 146: 815–816
- Schiff A A. Dosage of oral and depot fluphenazine (letter). American Journal of Psychiatry 1989; 146: 1233
- American Psychiatric Association. Treatments of psychiatric disorders: a task force report of the American Psychiatric Association. American Psychiatric Association, Washington, DC 1989; Vol. 2: 1504